Crysvita®

Understanding Crysvita® 

Crysvita® (burosumab-twza) is a monoclonal antibody used to treat X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO)—both conditions that lead to low phosphate levels, weak bones, and skeletal deformities. Crysvita® is the first targeted therapy for XLH and TIO, addressing the underlying phosphate dysregulation rather than just managing symptoms with phosphate supplements and vitamin D.

How Crysvita® Works:

• Increases phosphate levels by regulating the activity of fibroblast growth factor 23 (FGF23).
• Improves bone strength and growth in patients with XLH.
• Reduces bone pain and fractures, significantly enhancing quality of life.

FDA Approval:

• Crysvita® (burosumab-twza): Approved in 2018.

For more information, please visit the Crysvita® patient website and speak with your healthcare provider to determine if Crysvita® is the right treatment option for you.